Pregnancy and virologic response to antiretroviral therapy in South Africa

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Westreich, Daniel ^a,b   Cole, Stephen R ^b   Nagar, Shashi ^c,d   Maskew, Mhairi ^c,d   van der Horst, Charles ^e   Sanne, Ian ^c,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d RIGHT TO CARE   (South Africa)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PREGNANCY; PROSPECTIVE STUDY; RISK ASSESSMENT; SOUTH AFRICA; TREATMENT OUTCOME; TREATMENT RESPONSE; MIDDLE AGED; PREGNANCY COMPLICATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 79960990936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022778     Document Type: Article

References (47)

1. UNAIDS (2009) 2009 AIDS Epidemic Update. Available: http://dataunaidsorg/pub/Report/2009/2009_epidemic_update_enpdf. Geneva.
2. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, et al. (2005) Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. Aids 19: 1525-1534.
3. UNAIDS/WHO (2007) AIDS Epidemic Update 2007 Geneva.
4. Black V, Hoffman RM, Sugar CA, Menon P, Venter F, et al. (2008) Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 49: 276-281.
5. Homsy J, Bunnell R, Moore D, King R, Malamba S, et al. (2009) Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study. PLoS ONE 4: e4149.
6. Prins M, Meyer L, Hessol NA, (2005) Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. Aids 19: 357-370.
7. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354: 795-802.
8. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, et al. (2001) Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). Aids 15: 1951-1957.
9. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, et al. (2004) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351: 229-240.
10. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, et al. (2005) Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 192: 30-36.
11. Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, et al. (2007) Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. Aids 21: 957-964.
12. Westreich D, Eron J, Behets F, Horst C, Van Rie A, (2007) Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. J Infect Dis 195: 837-846.
13. Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, et al. (2008) Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 46: 611-621.
14. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, et al. (2010) Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med 7: e1000229.
15. Kumar RM, Uduman SA, Khurrana AK, (1997) Impact of pregnancy on maternal AIDS. J Reprod Med 42: 429-434.
16. Burns DN, Landesman S, Minkoff H, Wright DJ, Waters D, et al. (1998) The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol 178: 355-359.
17. French R, Brocklehurst P, (1998) The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 105: 827-835.
18. Saada M, Le Chenadec J, Berrebi A, Bongain A, Delfraissy JF, et al. (2000) Pregnancy and progression to AIDS: results of the French prospective cohorts. SEROGEST and SEROCO Study Groups. Aids 14: 2355-2360.
19. Lieve VP, Shafer LA, Mayanja BN, Whitworth JA, Grosskurth H, (2007) Effect of pregnancy on HIV disease progression and survival among women in rural Uganda. Trop Med Int Health 12: 920-928.
20. Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, et al. (2003) The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol 189: 552-559.
21. Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, et al. (2007) Pregnancy and HIV Disease Progression during the Era of Highly Active Antiretroviral Therapy. J Infect Dis 196: 1044-1052.
22. Keiser O, Gayet-Ageron A, Rudin C, Brinkhof MW, Gremlich E, et al. (2008) Antiretroviral treatment during pregnancy. Aids 22: 2323-2330.
23. Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Barkanic G, et al. (2009) Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response. PLoS ONE 4: e6961.
24. Watts DH, Lu M, Thompson B, Tuomala RE, Meyer WA 3rd, et al. (2009) Treatment interruption after pregnancy: effects on disease progression and laboratory findings. Infect Dis Obstet Gynecol 2009: 456717.
25. MacCarthy S, Laher F, Nduna M, Farlane L, (2009) Responding to Her Question: A Review of the Influence of Pregnancy on HIV Disease Progression in the Context of Expanded Access to HAART in Sub-Saharan Africa. AIDS Behavior.
26. WHO (2006) Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings: Towards universal access. Recommendations for a public health approach. Geneva. Available: www.who.int/hiv/pub/mtct/pmtct/: WHO.
27. Mirochnick M, Capparelli E, (2004) Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 43: 1071-1087.
28. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, et al. (2006) Reduced lopinavir exposure during pregnancy. Aids 20: 1931-1939.
29. Floridia M, Giuliano M, Palmisano L, Vella S, (2008) Gender differences in the treatment of HIV infection. Pharmacol Res 58: 173-182.
30. Aweeka F, Tierney C, Stek A, Sun X, Cohn S, et al. (2007) ACTG 5153s: Pharmacokinetic Exposure and Virological Response in HIV-1-infected Pregnant Women Treated with PI. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA. Abstract 739.
31. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F, (2008) Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 66: 179-195.
32. Zhang M, Huang Q, Huang Y, Wood O, Yuan W, et al. (2008) beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL. Retrovirology 5: 82.
33. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, et al. (2009) Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc 12: 38.
34. Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, et al. (2009) Effect of pulmonary tuberculosis on mortality in patients receiving HAART. Aids 23: 707-715.
35. Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, et al. (2009) Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 48: 1617-1623.
36. Ray WA, (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158: 915-920.
37. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106.
38. Hernán MA, Brumback B, Robins JM, (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: 561-570.
39. Robins JM, Hernán MA, Brumback B, (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560.
40. Westreich D, Cole SR, Tien PC, Chmiel JS, Kingsley L, et al. (2010) Time scale and adjusted survival curves for marginal structural cox models. Am J Epidemiol 171: 691-700.
41. Hernán MA, Robins JM, (2006) Estimating causal effects from epidemiological data. J Epidemiol Community Health 60: 578-586.
42. Cole SR, Hernan MA, (2008) Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168: 656-664.
43. Westreich D, Cole SR, (2010) Invited commentary: positivity in practice. Am J Epidemiol 171: 674-677; discussion 678-681.
44. Sha BE, Tierney C, Cohn SE, Sun X, Coombs RW, et al. (2011) Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials 12: 9-23.
45. Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, et al. (2003) Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158: 687-694.
46. Petersen ML, Wang Y, van der Laan MJ, Bangsberg DR, (2006) Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr 43 (Suppl 1): S96-S103.
47. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, et al. (2002) Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 35: 313-322.